Therapy for sarcoidosis: evidence-based recommendations

References

• Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/World association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc. Diffuse Lung Dis.16, 149–173 (1999).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Teirstein AS, Judson MA et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am. J. Respir. Crit. Care Med.164, 1885–1889 (2001).
   PubMed Web of Science ®Google Scholar
• Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis15, 52–58 (1998).
   Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest111(3), 623–631 (1997).
   PubMed Web of Science ®Google Scholar
• Gibson GJ, Prescott RJ, Muers MF et al. British thoracic society sarcoidosis study: effects of long term corticosteroid treatment. Thorax51(3), 238–247 (1996).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein A et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Q. J. Med.99(5), 307–315 (2006).
   Google Scholar
• Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin. Chest Med.29(3), 533–548 (2008).
   PubMed Web of Science ®Google Scholar
• Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q. J. Med.208, 525–533 (1983).
   Google Scholar
• Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influences the disease course. Am. J. Respir. Crit. Care Med.179(4), 307–312 (2009).
   PubMed Web of Science ®Google Scholar
• Bogunia-Kubik K, Tomeczko J, Suchnicki K, Lange A. HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens57(1), 87–90 (2001).
   PubMedGoogle Scholar
• Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M. The role of tumor necrosis factor α G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens75(3), 262–268 (2010).
   PubMedGoogle Scholar
• Grubic Z, Peros-Golubicic T, Stingl K, Zunec R. The investigation of HLA microsatellites influence in predisposition to sarcoidosis among Croatians. Sarcoidosis Vasc. Diffuse Lung Dis.28(1), 18–26 (2011).
   PubMedGoogle Scholar
• Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins hospital. Medicine78, 65–111 (1999).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Tami T. Upper airway. 4: sarcoidosis of the upper respiratory tract (SURT). Thorax65(2), 181–186 (2010).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nagai S, Balter M et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc. Diffuse Lung Dis.28(1), 56–64 (2011).
   PubMed Web of Science ®Google Scholar
• Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest135(2), 468–476 (2009).
   PubMed Web of Science ®Google Scholar
• Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurologic sarcoidosis. Arch. Intern. Med.157, 1864–1868 (1997).
   PubMed Web of Science ®Google Scholar
• Chambellan A, Turbie P, Nunes H, Brauner M, Battesti JP, Valeyre D. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest127(2), 472–481 (2005).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Selroos O. Evidence-based approach to the treatment of sarcoidosis. In: Evidence-Based Respiratory Medicine. Gibson PG, Abramson M, Wood-Baker R, Volmick J, Hensley M, Costabel U (Eds). Malden, Blackwell Publishing Ltd., Oxford, UK, 491–508 (2005).
   Google Scholar
• Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA287, 1301–1307 (2002).
   PubMed Web of Science ®Google Scholar
• Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst. Rev.3, CD003536 (2003).
   Google Scholar
• Bradley B, Branley HM, Egan JJ et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax63(Suppl. 5), S1–S58 (2008).
   Web of Science ®Google Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br. Med. J.4, 1165–1172 (1961).
   Google Scholar
• Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis – results of a cooperative study in former West Germany and Switzerland. WATL study group. Wissenschaftliche arbeitsgemeinschaft fur die therapie von lungenkrankheitan. Sarcoidosis Vasc. Diffuse Lung Dis.15(2), 178–182 (1998).
   PubMed Web of Science ®Google Scholar
• Nagai S, Shigematsu M, Hamada K, Izumi T. Clinical courses and prognoses of pulmonary sarcoidosis. Curr. Opin. Pulm. Med.5(5), 293–298 (1999).
   PubMedGoogle Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Finnish pulmonary sarcoidosis study group. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest116, 424–431 (1999).
   PubMed Web of Science ®Google Scholar
• Yeager H, Rossman MD, Baughman RP et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc. Diffuse Lung Dis.22(2), 147–153 (2005).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Shipley R, Desai S et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest136, 526–535 (2009).
   PubMed Web of Science ®Google Scholar
• Oberstein A, von Zitzewitz H, Schweden F, Muller-Quernheim J. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc. Diffuse Lung Dis.14(1), 65–72 (1997).
   PubMed Web of Science ®Google Scholar
• Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest128(3), 1483–1489 (2005).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest138, 1078–1085 (2010).
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Capron F et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax61(1), 68–74 (2006).
   PubMed Web of Science ®Google Scholar
• Spruit MA, Thomeer MJ, Gosselink R et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax60(1), 32–38 (2005).
   PubMed Web of Science ®Google Scholar
• Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest120(1), 102–108 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson LR, Brownsberger R, Raghu G. Respiratory failure and hypoventilation secondary to neurosarcoidosis. Am. J. Respir. Crit. Care Med.157(4 Pt 1), 1316–1318 (1998).
   PubMed Web of Science ®Google Scholar
• de Kleijn WP, de Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr. Opin. Pulm. Med.15(5), 499–506 (2009).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest132(1), 207–213 (2007).
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Lindholm A, Haahtela T, Tukiainen P, Selroos O. Inhaled budesonide for treatment of pulmonary sarcoidosis. Results of a double-blind, placebo-controlled, multicentre study. Eur. Respir. J.9(2 Suppl. 23), S406 (1996).
   PubMedGoogle Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. The Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage 2 sarcoidosis improves 5-year pulmonary function. Chest121, 24–31 (2002).
   PubMed Web of Science ®Google Scholar
• McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am. J. Med. Sci.339(1), 1–4 (2010).
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir. Med.104(5), 717–723 (2010).
   PubMed Web of Science ®Google Scholar
• Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J. Intern. Med.236(3), 285–290 (1994).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Iannuzzi MC, Lower EE et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.19(3), 198–204 (2002).
   PubMed Web of Science ®Google Scholar
• du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic follow-up pulmonary sarcoidosis: a pilot study. Eur. Respir. J.13(6), 1345–1350 (1999).
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch. Intern. Med.155, 846–851 (1995).
   PubMedGoogle Scholar
• Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr. Opin. Pulm. Med.8(5), 470–476 (2002).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc. Diffuse Lung Dis.17, 60–66 (2000).
   PubMed Web of Science ®Google Scholar
• Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J. Am. Acad. Dermatol.24, 451–454 (1991).
   PubMed Web of Science ®Google Scholar
• Dev S, McCallum RM, Jaffe GJ. Methotrexate for sarcoid-associated panuveitis. Ophthalmology106, 111–118 (1999).
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic nonifectious uveitis: analysis of a case series of 160 patients. Ophthalmology108, 1134–1139 (2001).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Kaufman AH. Use of cytotoxic therapy for chronic opthalmic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.16, S17 (1999).
   Google Scholar
• Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am. J. Med. Sci.299, 153–157 (1990).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch. Intern. Med.163(5), 615–620 (2003).
   PubMedGoogle Scholar
• Zisman DA, McCune WJ, Tino G, Lynch JP 3rd. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc. Diffuse Lung Dis.18(3), 243–252 (2001).
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur. Respir. J.14(5), 1117–1122 (1999).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis14, 121–130 (1997).
   Google Scholar
• Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.16, 87–92 (1999).
   PubMed Web of Science ®Google Scholar
• Kennedy PT, Zakaria N, Modawi SB et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur. J. Gastroenterol. Hepatol.18(7), 721–726 (2006).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.21, 43–48 (2004).
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur. Respir. J.38(5), 1145–1150 (2011).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Caldwell JR, Cannon GW et al. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: a double-blind placebo controlled study. Arthritis Rheum.43, S224 (2000).
   Google Scholar
• Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford)39(6), 655–665 (2000).
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Rothe E, Zissel G, Muller-Quernheim J. Exaggerated TNFα release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.19, 185–190 (2002).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc. Diffuse Lung Dis.25, 76–89 (2008).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.18, 70–74 (2001).
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest127(3), 1064–1071 (2005).
   PubMed Web of Science ®Google Scholar
• Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir. Med.100(11), 2053–2059 (2006).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Bradley DA, Lower EE. Infliximab for chronic ocular inflammation. Int. J. Clin. Pharmacol. Ther.43, 7–11 (2005).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med.174(7), 795–802 (2006).
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP et al. A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.23, 201–208 (2006).
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur. Respir. J.31(6), 1189–1196 (2008).
   PubMed Web of Science ®Google Scholar
• Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology72(4), 337–340 (2009).
   PubMed Web of Science ®Google Scholar
• Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir. Med.103(2), 268–273 (2009).
   PubMed Web of Science ®Google Scholar
• Lahmer T, Knopf A, Lanzl I, Heemann U, Thuermel K. Using TNF-α antagonist Adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol. Int. doi:10.1007/s00296-011-1968-x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia13, S47–S50 (2007).
   Google Scholar
• Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin. Exp. Dermatol.35(7), 795–796 (2010).
   PubMedGoogle Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 19, 146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle48, 257–272 (1967).
   PubMedGoogle Scholar
• Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med. Scand.425, S302–S308 (1964).
   Google Scholar
• Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med.160(1), 192–197 (1999).
   PubMed Web of Science ®Google Scholar
• Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br. J. Dermatol.148(1), 147–148 (2003).
   PubMed Web of Science ®Google Scholar
• Varron L, Broussolle C, Candessanche JP et al. Spinal cord sarcoidosis: report of seven cases. Eur. J. Neurol.16(3), 289–296 (2009).
   PubMed Web of Science ®Google Scholar
• Bichari W, Bartiromo M, Mohey H et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant. Proc.41(2), 672–673 (2009).
   PubMed Web of Science ®Google Scholar
• Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs69(16), 2227–2243 (2009).
   PubMed Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med.155, 1665–1669 (1997).
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana JR, Babaali H et al. Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.26, 121–131 (2009).
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br. J. Pharmacol.159(4), 842–855 (2010).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest122, 227–232 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen YT, Dupuy A, Cordoliani F et al. Treatment of cutaneous sarcoidosis with thalidomide. J. Am. Acad. Dermatol.50(2), 235–241 (2004).
   PubMed Web of Science ®Google Scholar
• Belkhou A, Younsi R, El Bouchti I, El Hassani S. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine75(4), 511–512 (2008).
   PubMed Web of Science ®Google Scholar
• Dasilva V, Breuil V, Chevallier P, Euller-Ziegler L. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFα blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine77(1), 82–83 (2010).
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma.48(7), 1307–1312 (2007).
   PubMed Web of Science ®Google Scholar
• Gribbin J, Hubbard RB, Le JI, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax61(11), 980–985 (2006).
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Huie TJ et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am. J. Respir. Crit. Care Med.183(11), 1524–1530 (2011).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis14, 154–158 (1997).
   Google Scholar
• Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest121, 32–39 (2002).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nagai S, Balter M et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc. Diffuse Lung Dis.28(1), 56–64 (2011).
   PubMed Web of Science ®Google Scholar
• James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet2, 526–528 (1967).
   PubMedGoogle Scholar
• Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am. Rev. Respir. Dis.107, 609–614 (1973).
   PubMed Web of Science ®Google Scholar
• Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. Scand. J. Respir. Dis.60, 215–221 (1979).
   PubMedGoogle Scholar
• Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis: a five year controlled follow-up. NY State J. Med.87, 496–499 (1987).
   PubMedGoogle Scholar
• Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.23(1), 51–57 (2006).
   PubMed Web of Science ®Google Scholar
• Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am. J. Respir. Crit. Care Med.156, 1571–1576 (1997).
   Web of Science ®Google Scholar
• Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.27, 49–56 (2010).
   PubMed Web of Science ®Google Scholar